Clinical Trial Update: Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy [Phase 3]

View source ↗

Summary

A Phase III trial evaluating RAD001 (everolimus) as adjuvant therapy in poor-risk diffuse large B-cell lymphoma after complete response to rituximab-chemotherap…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• RAD001 (Everolimus) (everolimus)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Diffuse Large B-cell Lymphoma | Phase 3 | Status: COMPLETED | Results posted: 2017-07-12